Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

19.37USD
22 Jun 2018
Change (% chg)

$-0.18 (-0.92%)
Prev Close
$19.55
Open
$19.75
Day's High
$19.76
Day's Low
$18.86
Volume
1,620,415
Avg. Vol
757,564
52-wk High
$20.20
52-wk Low
$7.15

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $2,368.37
Shares Outstanding(Mil.): 192.24
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.72 -- --
ROI: -71.65 2.00 14.38
ROE: -- 3.49 16.08

BRIEF-Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald

* ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING

09 May 2018

BRIEF-Array Biopharma Reports Q3 Loss Per Share $0.11

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2018

09 May 2018

Array melanoma drugs show significant survival versus Roche drug in study

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

06 Feb 2018

UPDATE 1-Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

06 Feb 2018

BRIEF-Array Biopharma Q2 Loss Per Share $0.17

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

06 Feb 2018

Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

06 Feb 2018

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

02 Feb 2018

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK Array BioPharma Inc on Thursday sued AstraZeneca AB , accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion (5.96 billion pounds) collaboration with Merck & Co .

01 Feb 2018

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK, Feb 1 Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

01 Feb 2018

BRIEF-Array Biopharma Says Its partner Seeks Withdrawal of Marketing Authorization Applications For Binimetinib Monotherapy in EU, Switzerland And Australia

* ARRAY BIOPHARMA SAYS PIERRE FABRE MEDICAMENT, REQUESTED THAT MARKETING AUTHORIZATION APPLICATIONS FOR BINIMETINIB MONOTHERAPY BE WITHDRAWN

23 Jan 2018

Competitors

Earnings vs. Estimates